• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [25150 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2026     National Institute for Health and Care Excellence (NICE) Obinutuzumab with mycophenolate mofetil for treating lupus nephritis. NICE technology appraisal guidance 1131
2026     National Institute for Health and Care Excellence (NICE) Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 1130
2026     National Institute for Health and Care Excellence (NICE) Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer. NICE technology appraisal guidance 1127
2026     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Nirmatrelvir plus ritonavir (Paxlovid)]
2026     National Institute for Health and Care Excellence (NICE) Targeted-release budesonide for treating primary IgA nephropathy. NICE technology appraisal guidance 1128
2026     National Institute for Health and Care Excellence (NICE) Leadless cardiac pacemaker implantation for bradyarrhythmias. NICE HealthTech guidance 770
2026     National Institute for Health and Care Excellence (NICE) Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation. NICE HealthTech guidance 771
2026     National Institute for Health and Care Excellence (NICE) Pulmonary artery pressure technologies for remote monitoring of chronic heart failure. NICE HealthTech guidance 769
2026     National Institute for Health and Care Excellence (NICE) Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2. NICE highly specialised technologies guidance 34
2026     Swiss Federal Office of Public Health (FOPH) Superficial/deep heat in physiotherapy for musculoskeletal conditions
2026     Swiss Federal Office of Public Health (FOPH) Injection therapies with corticosteroids for chronic tendinopathy or enthesopathy
2026     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study
2026     Swiss Federal Office of Public Health (FOPH) Thermoablation for benign thyroid nodules
2026     NIHR Health Services and Delivery Research programme Digital alerting to improve sepsis detection and patient outcomes in NHS Trusts: a multi-methods study
2026     NIHR Health Technology Assessment programme Effectiveness of polyhexanide, chlorhexidine with neomycin and mupirocin for nasal methicillin-resistant Staphylococcus aureus (MRSA) decolonisation: non-inferiority RCT (TIDE)
2026     NIHR Health Technology Assessment programme Views on outpatient paracentesis and GnRH antagonists for ovarian hyperstimulation syndrome: a qualitative study of patients and healthcare professionals
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Targeted lung denervation using catheter ablation in patients with moderate to severe chronic obstructive pulmonary disease that cannot be treated or cannot be adequately treated with medication]
2026     NIHR Health Technology Assessment programme Removal of small fibroids and polyps in patients with infertility and recurrent miscarriage: The HELP Fertility? RCT
2026     Health Information and Quality Authority (HIQA) Rapid health technology assessment on the use of vesicostomy buttons in children
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer, non-advanced) – Addendum to Project A25-96]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Donanemab (early Alzheimer’s disease) – Benefit assessment according to §35a Social Code Book V]
2026     Health Technology Wales (HTW) Capsule sponge devices to detect Barrett’s oesophagus and early-stage oesophageal cancer
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avapritinib (indolent systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avapritinib (advanced systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vimseltinib (symptomatic tenosynovial giant cell tumours) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Reinforced foster homes]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Percutaneously implanted interatrial shunt for the treatment of heart failure with reduced left ventricular ejection fraction (LVEF < 40 %) – Addendum to Project N24-04]
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Barriers and facilitators when implementing guidelines in health and social care for the elderly]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vorasidenib (astrocytoma or oligodendroglioma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lattice radiotherapy in the curative or palliative treatment of deep, large-volume tumors and metastatic or unresectable disease]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (head and neck squamous cell carcinoma) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asciminib (CML, first- and second-line treatment) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olezarsen (chylomicronaemia syndrome) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of a decision aid for carotid revascularization surgery for carotid stenosis]
2026     Agency for Care Effectiveness (ACE) Phagenyx to improve swallowing in severe post-stroke dysphagia
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vutrisiran (transthyretin amyloidosis with cardiomyopathy) – Addendum to Project A25-93]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sebetralstat (acute attacks of hereditary angioedema ≥ 12 years) – Assessment according to §35a (para. 1, sentence 11) Social]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avapritinib (gastrointestinal stromal tumours) – Benefit assessment according to §35a Social Code Book V]
2026     Health Information and Quality Authority (HIQA) Scalable Training and Knowledge Exchange on guideline development for patients, public, and healthcare professionals (The STAKEholder Project)
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Momelotinib (myelofibrosis) – Benefit assessment according to §35a Social Code Book V]
2026     Agency for Healthcare Research and Quality (AHRQ) Dietary total fat intake and dietary polyunsaturated fatty acid intake and child growth and development outcomes: a systematic review
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Diflunisal (hereditary transthyretin amyloidosis with polyneuropathy) – Benefit assessment according to §35a Social Code Book V]
2026     Agency for Healthcare Research and Quality (AHRQ) Medical care for adults with Down syndrome
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezepelumab (chronic rhinosinusitis with nasal polyps) – Benefit assessment according to §35a Social Code Book V]
2026     Agency for Healthcare Research and Quality (AHRQ) Prehospital EMS blood transfusion and fluid interventions for hemorrhagic shock
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, >= 3 to < 18 years) – Benefit assessment according to §35a Social Code Book V]
2026     Agency for Healthcare Research and Quality (AHRQ) Recurrent nephrolithiasis in adults and children: comparative effectiveness of preventive medical strategies
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selumetinib (plexiform neurofibromas in adults with neurofibromatosis type 1) – Benefit assessment according to §35a Social Code Book V]
2026     NIHR Health Technology Assessment programme Mammographic surveillance in breast cancer patients aged 50 years or older: a synopsis of the Mammo-50 RCT
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lecanemab (early Alzheimer’s disease) – Addendum to Project A25-111]
2026     NIHR Health Technology Assessment programme Olanzapine for young people with anorexia nervosa: a synopsis of the main results from the OPEN open-label feasibility study
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Neuromuscular electrostimulation of the common peroneal nerve for the treatment of venous leg ulcers]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Addendum to Project A25-108]
2026     NIHR Health Technology Assessment programme Effects of physical activity and diet in pregnancy to prevent gestational diabetes: an individual participant data (IPD) meta-analysis on the differential effects of interventions with economic evaluation
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risk-adapted PSA and MRI screening for early detection of prostate cancer]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (smouldering multiple myeloma) – Addendum to Project A25-109]
2026     NIHR Health Technology Assessment programme Fenofibrate and progression of retinopathy in adults with diabetes: the randomised placebo-controlled LENS trial
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for updating the DMP “asthma”]
2026     NIHR Health Technology Assessment programme Early stroke specialist vocational rehabilitation for REturn To work After stroKE: a synopsis from the RETAKE RCT
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for updating the DMP “breast cancer”]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety and surgical efficacy of robotic surgery for the implantation of deep brain stimulation electrodes in adults with movement disorders for which such surgery is indicated]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome in corrective surgery for anorectal malformations]
2026     NIHR Health Technology Assessment programme Effects and costs of a group-based educational intervention to reduce opioid use in people with chronic pain: I-WOTCH RCT
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests – serum folate testing]
2026     NIHR Health Technology Assessment programme Effectiveness of intensive community care services for adolescents with acute psychiatric emergencies: findings from a feasibility multi-centre, parallel-group, single-blinded RCT
2026     NIHR Health Technology Assessment programme Outpatient paracentesis for ovarian hyperstimulation syndrome: STOP-OHSS feasibility study and RCT synopsis
2026     Scottish Health Technologies Group (SHTG) Virtual wards
2026     Austrian Institute for Health Technology Assessment (AIHTA) Health economic reference cases and costing approaches – concepts, international practices and implications for Austria
2026     NIHR Health Technology Assessment programme Enabling health and maintaining independence for older people at home: the ‘HomeHealth’ randomised controlled trial
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests – vitamin B12 testing]
2026     Health Information and Quality Authority (HIQA) Health technology assessment of RSV immunisation
2026     Health Sciences Institute in Aragon (IACS) [Quantitative MALDI-TOF mass spectrometry in the diagnosis and monitoring of malignant monoclonal gammopathies]
2026     Health Sciences Institute in Aragon (IACS) [Contrast-enhanced mammography in the diagnostic process of breast cancer]
2026     Health Information and Quality Authority (HIQA) Scoping review: the association between herpes zoster vaccination and the risk of dementia
2026     Austrian Institute for Health Technology Assessment (AIHTA) [Infiltration therapies for musculoskeletal pain: intradermal whealing]
2026     Health Information and Quality Authority (HIQA) A scoping review of publicly-funded services for donor-assisted human reproduction in selected countries
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Immunological panel for the evaluation of T cell responses to cytomegalovirus antigens in lung transplant recipients]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nirogacestat (desmoid tumour) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     NIHR Health Services and Delivery Research programme Evaluating the national rollout of the NHS App in England using qualitative and quantitative methods
2026     NIHR Health Technology Assessment programme Developing a national triage tool for use in NHS regional trauma networks: the MATTS mixed methods study
2026     Health Information and Quality Authority (HIQA) A health technology assessment (HTA) of cochlear implants for adults with single-sided deafness
2026     NIHR Health Technology Assessment programme Seizure prophylaxis in glioma surgery: a synopsis from the SPRING RCT
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Early treatment response prediction marker based on the clearance of blast cells in peripheral blood in acute myeloid leukaemia]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal shockwave therapy for treating chronic skin wounds: pressure ulcers, diabetic foot ulcers, and vascular wounds (venous and/or arterial)]
2026     NIHR Health Technology Assessment programme Identifying the best diagnostic test for ovarian cancer – synopsis of Refining Ovarian Cancer Test accuracy Scores (ROCkeTS) research
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Personalised treatment protocol with rituximab based on artificial intelligence in membranous nephropathy]
2026     NIHR Health Technology Assessment programme Implementation of eye screening programmes for patients with diabetes: a systematic map of evidence from five countries
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Mass spectrometry from blood samples for the detection of minimal residual disease in patients with multiple myeloma]
2026     NIHR Health Technology Assessment programme Surgery versus non-surgical splint treatment for proximal phalanx shaft finger fractures in adults: the POINT Randomised Controlled Trial
2026     NIHR Health Services and Delivery Research programme Accounting for unmet need in equitable healthcare resource allocation: synopsis
2026     NIHR Health Technology Assessment programme Prophylactic antibiotics to prevent chest infections in children with neurological impairment: the PARROT RCT
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests – erythrocyte sedimentation rate test]
2026     NIHR Health Services and Delivery Research programme ‘Tired of spinning plates’: Synopsis of mixed methods exploration of mental health experiences of adult/older carers of adults with learning disabilities
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Treatment of amblyopia in the pediatric population through dichoptic therapy]
2026     NIHR Health Technology Assessment programme The work and vocational advice intervention for adults in full or part-time employment: a synopsis of the WAVE feasibility study and RCT
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Early treatment response prognostic marker based on the elimination of blast cells in peripheral blood in acute myeloid leukemia]
2026     NIHR Health Technology Assessment programme BEhavioural Weight Management: COMponents of Effectiveness (BE:COME) Synopsis
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Art therapy: visual arts in the management of mild cognitive impairment]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Hugging for pain, depression and anxiety relief]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, clinical effectiveness and cost-effectiveness of neonatal screening for Pompe disease]